The Latest Cardiac and Vascular News
Phase 1 clinical trial (CHIHUAHUA) demonstrates that single dose of second-generation DSR product (DSR 2.0) is safe and well-tolerated, and indicates a compelling dosing profile On track to file INDi application to US FDA in Q1 2023 Start of MOJAVE, a US multi-center randomized controlled Phase 1/2a clinical trial of […]
Ghent, BELGIUM – 6 July 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the positive results from its RED DESERT study of alfapump DSR® (Direct Sodium Removal) which were presented at the Heart Failure […]
GHENT, Belgium, Feb. 16, 2021 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces, in accordance with Article 15 of the Belgian Act of 2 May 2007 on the disclosure of […]
Live webcast with Dr. Jeffrey Testani on 11 December 2020 at 03:00pm CET/09:00am EST GHENT, Belgium, Dec. 07, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that it will hold a key opinion […]
Results from first 13 patients in Roll-In Cohort showed over 90% reduction in mean frequency of therapeutic paracentesis versus baseline Indication of rapid and persistent clinically relevant improvement in patients’ quality of life Safety profile in line with expectations Interim data of the full Roll-In Cohort expected in H1 2021 Conference call with live webcast presentation today at 02:00 pm CET / 08:00 am EDT GHENT, Belgium, […]
RED DESERT: Results from first five patients indicaterepeated dose alfapump DSR therapy to be safeandeffective Interim data support DSR hypothesis: kidneys eliminate free water to maintain patients’ serum sodium levels No patients required loop diuretic therapy during the six-week alfapump DSR treatment period Followingalfapump DSR treatment, loop diuretic responsiveness was restored to near normal levels; effect was durable for months post-treatmentwith majority of patients requiring little or no diuretic therapy Full RED DESERT data on track […]
Ghent, BELGIUM – 28 May 2020 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, announces that all proposed resolutions submitted to the Annual and Extraordinary General Meeting of Shareholders were approved […]
GHENT, Belgium, May 04, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces the appointment of Oliver Gödje, MD, PhD, as Chief Medical Officer, with immediate effect. Dr Gödje replaces Gijs Klarenbeek, MD, […]
THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 22 January 2020, 15:50 CET Ghent, Belgium, 22 January 2020 – Sequana Medical […]
The study aims to: Evaluate the safety of alfapump DSR in patients with heart failure Assess the feasibility of alfapump DSR to remove excess sodium and fluid from the body Explore the potential impact of DSR therapy to restore response to diuretics GHENT, Belgium, Jan. 07, 2020 (GLOBE NEWSWIRE) — Sequana Medical NV […]
